In addition to germline BRCA1/2 mutations, silencing of BRCA1/2 expression can also occur via epigenetic processes such as promoter hyper- methylation and this has been documented in 11-14% of breast cancers [2] and 11-35% of ovarian cancer patients [3]. Here, BRCA1 is linked to breast carcinoma.